

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

ANNOUNCEMENT ON RECEIPT OF DRUG REGISTRATION CERTIFICATE BY XINXIN PHARMACEUTICAL PLANT (新新制药厂) OF THE COMPANY

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board wishes to announce that Xinxin Pharmaceutical Plant (新新制药厂), a branch of the Company, has recently received a Drug Registration Certificate (《药品注册证书》) (the “**Drug Registration Certificate**”) issued by the National Medical Products Administration of the People's Republic of China (国家药品监督管理局) in respect of Loxoprofen Sodium Cataplasms (洛索洛芬钠凝胶贴膏) (the “**Drug**”). The key details of the Drug Registration Certificate and the other relevant information on the Drug are set out in **Appendix A** to this announcement.

2. IMPACT ON THE COMPANY

The Company places great emphasis on pharmaceutical research and development (“**R&D**”) and exercises strict quality and safety controls across the entire chain of drug R&D, manufacturing, and distribution. The Drug was submitted for registration as a Category 4 chemical drug. Upon approval, the Drug is deemed to have passed the quality and efficacy consistency evaluation with the reference-listed drug. The approval for registration of the Drug, which signifies that it meets the relevant requirements for drug registration, is not expected to have a material impact on the Company's short-term financial performance.

3. CAUTION IN TRADING

There may be uncertainties during the period from marketing approval to actual production and sales of the Drug. Factors such as national policies and market conditions may affect the scale of future production and sales of the Drug.

Shareholders and potential investors are advised to exercise caution when trading in the shares of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
25 November 2025

APPENDIX A

1. Key Details of the Drug Registration Certificate

一、药品注册证书的主要内容

Drug Name 药品名称	: Loxoprofen Sodium Cataplasms 洛索洛芬钠凝胶贴膏
Dosage Form 剂型	: Cataplasm 贴膏剂
Specification 规格	: Each patch (14 cm × 10 cm) contains 10g of formulation, including 100mg of loxoprofen sodium (calculated as C ₁₅ H ₁₇ NaO ₃) 每贴 (14 cm × 10 cm) 含膏量 10g, 含洛索洛芬钠 100mg (C ₁₅ H ₁₇ NaO ₃ 计)
Registration Classification 注册分类	: Class 4 Chemical Drug 化学药品 4 类
Marketing Authorisation Holder 上市许可持有人	: Xinxin Pharmaceutical Plant of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited 津药达仁堂集团股份有限公司新新制药厂
Manufacturer 生产企业	: Beijing Baiao Pharmaceutical Co., Ltd 北京百奥药业有限责任公司
Drug Registration Standard Number 药品注册标准编号	: YBH28222025
Application Number 受理号	: CYHS2401465; CYHB2501432
Application Type 受理事项	: Drug Registration (Domestic Manufacture) 药品注册 (境内生产)
Certificate Number 证书编号	: 2025S03428
Drug Approval Number 药品批准文号	: National Medical Products Administration Approval No. (known as "Guo Yao Zhun Zi" in Chinese regulatory terminology) H20255958 国药准字 H20255958
Validity Period of the Drug Approval Number 药品批准文号有效期	: Until 17 November 2030 至 2030 年 11 月 17 日

Approval Conclusion : Pursuant to the applicable laws and regulations, including *Drug Administration Law of the People's Republic of China* (《中华人民共和国药品管理法》), and upon review, this drug meets the relevant requirements for drug registration. Approval is hereby granted for registration. The quality standards, package insert, labeling, and manufacturing process shall be implemented in accordance with the approved versions attached to this certificate. The drug manufacturing enterprise shall comply with Good Manufacturing Practice (GMP) requirements before commencing production and sale.

审批结论 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。

2. Other Relevant Information on the Drug

二、药品的其他相关情况

The Drug (i.e. Loxoprofen Sodium Cataplasms) is indicated for the relief of inflammation and pain associated with osteoarthritis, muscle pain, and post-traumatic swelling and pain. The Drug was originally developed by LEAD CHEMICAL CO., LTD. and has long been one of the top-selling analgesics in the Chinese market. According to statistics from the Menet database, the Drug has consistently achieved double-digit growth in recent years. In 2024, total nationwide sales exceeded RMB1,700 million, while sales in the first half of 2025 surpassed RMB980 million.

洛索洛芬钠凝胶贴膏用于以下疾病及症状的消炎、镇痛：骨关节炎、肌肉痛、外伤后的肿胀疼痛。本品由 LEAD CHEMICAL CO., LTD. 原研开发，是中国市场长期销量领先的镇痛类药物之一。根据米内数据库显示，洛索洛芬钠凝胶贴膏近年来始终保持超 2 位数的增速，2024 年全国总销售额超 17 亿元，2025 年上半年销售额超 9.8 亿元。

The Drug is the Company's first modern gel-type cataplasm approved for marketing following a deemed quality and efficacy consistency evaluation with the reference-listed drug, marking a significant milestone in the Company's strategic expansion into the field of transdermal drug delivery. As at the date of this announcement, the cumulative R&D investment in the Loxoprofen Sodium Cataplasms project amounts to approximately RMB37.88 million. Leveraging the development of the Drug as a strategic entry point, the Company has established a modern Chinese medicine cataplasm technology platform with full-process capabilities covering R&D, manufacturing, and quality control. This platform integrates advanced technologies of modern cataplasm formulations with the principles of traditional Chinese medicine. Moving forward, the Company will continue to expand its product portfolio across chemical drugs, traditional Chinese medicines, and wellness patches, with the aim of providing patients with a broader range of therapeutic options and improving the overall medication experience.

洛索洛芬钠凝胶贴膏是津药达仁堂首个视同通过仿制药质量与疗效一致性评价获批上市的现代凝胶贴膏剂产品，标志着公司在经皮给药领域的战略布局取得关键性里程碑成果。截至目前，洛索洛芬钠凝胶贴膏项目累计研发投入约 3788 万元。以本品种开发为切入点，津药达仁堂打造了具有“研发-生产-质控”全流程开发能力现代中药贴剂技术平台，实现现代贴膏剂先进技术与传统中药的有机结合，后续将持续构建覆盖“化药-中药-健康贴”的产品矩阵，为广大患者提供更多的用药选择，改善用药体验。